As of September 27, 2023, Baxter International (BAX) experienced a significant drop in its stock price, reaching a new 52-week low at $37.34. This decline was highlighted in a table published by the Wall Street Journal on September 20, 2023, which displayed the highest and lowest prices reached during that day’s trading session. BAX’s new 52-week low was recorded at $37.195. Barchart.com also identified BAX as one of the US exchanges’ 52-week new lows on September 22, 2023.
According to Seeking Alpha, on August 29, 2022, BAX had previously hit a 52-week low at $56.40. Furthermore, the report stated that year to date, BAX shares had experienced a significant decrease of 34%.
Baxter International Inc.
Updated on: 05/12/2023
Debt to equity ratio: Strong Buy
Price to earnings ratio: Strong Buy
Price to book ratio: Strong Buy
DCF: Strong Buy
We did not find social sentiment data for this stock
|Analyst / firm||Rating|
BAX Stock Performance and Financial Analysis: September 27, 2023
On September 27, 2023, BAX stock had a mixed performance in the market. The stock opened at $37.43, slightly higher than the previous day’s close of $37.32. Throughout the day, the stock’s price fluctuated within a range of $37.06 to $37.63. The trading volume for the day was 1,672,562 shares, which was lower than the average volume of 4,498,825 shares over the past three months.
BAX, with a market capitalization of $19.1 billion, operates in the health technology sector, specifically in the medical specialties industry. The company is headquartered in Deerfield, Illinois.
Looking at the earnings growth, BAX experienced a significant decline in the past year, with earnings growth at -288.73%. However, for this year, the company’s earnings growth improved slightly to -16.88%. Over the next five years, BAX is expected to have a modest earnings growth of 0.33%.
In terms of revenue growth, BAX performed well in the last year, with a growth rate of 18.22%. This indicates that the company has been able to increase its sales and generate more revenue. The price-to-sales ratio stands at 1.70, suggesting that the market values the company’s sales at a relatively low multiple.
The price-to-book ratio, which compares the stock’s market value to its book value, is 3.26 for BAX. This indicates that the market is valuing the company’s assets at a higher multiple compared to its book value.
The company’s earnings per share (EPS) forecast for the current quarter is $0.80. This indicates the expected profitability of the company in the near term. In the previous year, BAX reported an annual revenue of $15.1 billion but suffered a net loss of $2.4 billion. The net profit margin for the company stands at -16.10%, indicating that the company’s expenses are currently outweighing its revenue.
On September 27, 2023, BAX’s stock performance was influenced by other companies in the medical specialties industry. Straumann Holding AG, a dental technology company, experienced a decline of 6.35% in its stock price. Zimmer Biomet Holding, a medical device company, also saw a decline of 2.44%. On the other hand, Insulet Corp, a provider of insulin delivery systems, saw an increase of 1.36% in its stock price.
Investors interested in BAX should keep an eye on the company’s next reporting date, which is scheduled for November 2, 2023. This report will provide more insights into the company’s financial performance and could impact its stock price.
In conclusion, BAX had a mixed performance on September 27, 2023. While the stock opened slightly higher and experienced some price fluctuations throughout the day, the trading volume was lower than average. The company’s earnings and revenue growth have shown mixed results, with a significant decline in earnings growth last year but a modest improvement this year. Investors should closely monitor BAX’s financial performance and upcoming reports to make informed investment decisions.
BAX Stock Shows Promising Performance: Median Target Price of $50.00 Indicates 34.01% Increase
BAX stock showed promising performances on September 27, 2023, with a median target price of $50.00, representing a 34.01% increase from the last recorded price of $37.31. The consensus among 17 investment analysts is to hold stock in Baxter International Inc, indicating optimism and stability. The current quarter’s earnings per share stood at $0.80, and the company reported sales of $3.9 billion for the same period, demonstrating a strong financial position. Investors should watch for the upcoming financial report on November 2 for further insight into the company’s performance.